Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hideho Okada, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00766753
First received: June 23, 2008
Last updated: November 18, 2013
Last verified: November 2013

June 23, 2008
November 18, 2013
December 2006
February 2014   (final data collection date for primary outcome measure)
The primary goal is to establish the safety of the approach. [ Time Frame: Continuous ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00766753 on ClinicalTrials.gov Archive Site
Assess the induction of systemic immune responses against GAAs [ Time Frame: Continuous ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas

This is a single-institution Phase I/II study designed to evaluate the safety and induction of an immune response, and preliminary clinical response of vaccinations with Type-1 alpha-DCs (alpha-DC1) loaded with glioma-associated antigen (GAA) epitopes and administration of poly-ICLC in patients with recurrent malignant gliomas. Approximately 30 subjects will be enrolled in this study at UPMC/UPCI Hillman Cancer Center. The study participants in this trial will be HLA-A2 positive male or female adults over 18 years of age. The primary objective is to establish the safety of this approach. The endpoints will be to determine the maximum tolerated dose (MTD) of alpha-DC1 vaccines in combination with a fixed dose of poly-ICLC, using standard criteria and close clinical followups. The secondary objectives are 1) to assess the immunological response against GAAs in patients with recurrent malignant gliomas immunized with DCs loaded with GAA-derived peptides using enzyme-linked immuno-spot (ELISPOT), delayed-type hypersensitivity (DTH) and tetramer assays; and 2) to assess the preliminary anti-tumor clinical activity of the vaccines as measured by radiological response (MRI), overall survival, and 4- and 6-month progression-free survival (PFS).

This is a single-institution Phase I/II study designed to evaluate the safety, the induction of an immune response, and the preliminary clinical response of vaccinations with Type-1 αDCs (αDC1) loaded with glioma-associated antigen (GAA) epitopes and administration of poly-ICLC in patients with recurrent malignant gliomas. The hypothesis is that this form of vaccines in combination with poly-ICLC treatment will prove to be safe, and will induce potent anti-glioma immune responses.

The primary objective is to establish the safety of the approach.

The secondary objectives are to 1) assess the immunological response against GAAs in patients with recurrent malignant gliomas immunized with DCs loaded with GAA-derived peptides using enzyme-linked immuno-spot (ELISPOT), delayed-type hypersensitivity (DTH) and tetramer assays and 2) assess the preliminary anti-tumor clinical activity of the vaccines as measured by radiological response (MRI), overall survival, and four- and six-month progression-free survival (PFS).

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Malignant Glioma
  • Biological: Dendritic vaccine pulsed with multiple peptides
    Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
  • Biological: The first booster vaccine phase:
    This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
  • Biological: The second booster vaccine phase:

    At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued up to five years from the initial vaccine (the first vaccine for the patient on Week 1). DC vaccines in this phase will be administered every 6 months+/- 2 weeks.

    2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays

Experimental: Single
All consenting, eligible subjects receive the intervention
Interventions:
  • Biological: Dendritic vaccine pulsed with multiple peptides
  • Biological: The first booster vaccine phase:
  • Biological: The second booster vaccine phase:
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
December 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have a histologically confirmed

    • recurrent glioblastoma (GBM)
    • anaplastic astrocytoma (AA)
    • anaplastic oligodendroglioma (AO)
    • anaplastic mixed oligoastrocytoma (AMO)
    • other anaplastic glioma
  • Patients must have received prior external beam radiotherapy and/or chemotherapy unless patients refused the options.
  • Patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy).
  • Patients must be HLA-A2 positive.
  • All patients must sign an informed consent document indicating that they are aware of the investigational nature of this study.
  • Patients must sign an authorization for the release of their protected health information.
  • Patients must be > 18 years old, and with a life expectancy > 8 weeks. -Patients must have a Karnofsky performance status of > 60.
  • Patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agent, 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 4 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). Any questions related to the definition of non-cytotoxic agents should be directed to the principal investigator.
  • Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism.
  • Patients must not have any serious concurrent medical illness.
  • Documented negative serum beta-HCG for female patients of child-bearing age.
  • Patients must be free of systemic infection. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.
  • Patients must have adequate organ function as measured by:

    1. Hematopoietic:

      • granulocytes at least 2500/mm3
      • lymphocytes at least 1000/mm3
      • platelets at least 100,000/mm3
      • hemoglobin at least 10.0 g/dL
    2. Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at rest must be at least 50% or within the normal range of the institution. A cardiology clearance will be required for LV ejection fraction 50%.
    3. Hepatic: AST, ALT, GGT, LDH, Alk phos within 2.5 x upper normal limit and total bilirubin no greater than 2.0 mg/dL.
    4. Renal: Serum creatinine up to 1.5 x upper normal limit.
    5. Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to 18 days of subject registration.

Exclusion Criteria:

  • Pregnant or breast-feeding.
  • Presence of metastatic disease.
  • Active bacterial, viral or fungal infections. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.
  • Chemotherapy, biologic therapy or radiation therapy less than one month prior to study entry.
  • History or presence of autoimmune disease.
  • Use of immunosuppressives within 4 weeks prior to study entry or anticipated use of immunosuppressive agents. Minimum doses of corticosteroid (dexamethasone up to 4 mg/day) is permitted.
  • Subjects with uncontrolled pain. -Subjects who have sensitivity to drugs to provide local anesthesia.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00766753
05-115, RO1 NS055140
Yes
Hideho Okada, University of Pittsburgh
Hideho Okada
Not Provided
Principal Investigator: Frank Lieberman, MD University of Pittsburgh
University of Pittsburgh
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP